drugset / Trial / NCT04590586
Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19. Candidate agents will be evaluated frequently for efficacy and safety, with candidate agents being added to and/or removed from the study on an ongoing basis, depending on the results of their evaluation.
Timeline
- Start
- 2020-11-24
- Primary completion
- 2021-08-03
- Completion
- 2021-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apremilast | Small molecule | 30 mg | Oral |
| Subject | Lanadelumab | Monoclonal antibody | 300 mg | Intravenous |
| Subject | Zilucoplan | Peptide | 32.4 mg | Subcutaneous |